Coherus pulls first interchangeable biosimilar win for Lucentis copycat
Move over, Lucentis. The FDA has approved the first interchangeable biosimilar to Roche’s blockbuster anti-VEGF drug.
Coherus’ Cimerli is expected to hit the market in October after getting the FDA’s thumbs-up in five retinal indications, the company announced on Tuesday. Cimerli isn’t the first biosimilar to rival Roche’s eye drug — but it is the first to win interchangeable status, meaning it can be substituted at the pharmacy in some cases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.